BariaTek, created by Truffle Capital in 2019, develops minimally invasive, endoscopically implantable devices that mimic the effect of bariatric surgery (or weight loss surgery) to treat severe obesity, a major unmet medical need, associated with an increased risk of heart disease, stroke, sleep apnea, and some types of cancers.
See website
Synoptical view
- First investment date
- 2019
Management team
In summary
BariaTek aims to develop endoscopic technologies to mimic the effects of bariatric surgery in terms of effectiveness but without the drawbacks (cumbersome, invasive, complications) and thus enable more obese patients to have a safe and effective solution for weight loss.
